CG-P5 peptide / Caregen - LARVOL DELTA

Caregen Unveils CG-P5, a Treatment for Wet Macular Degeneration, at APAO2025 [Google translation] (HIT News) - "Caregen, a biotechnology company...announced that it will unveil its wet macular degeneration treatment drug 'CG-P5' at the Asia Pacific Academy of Ophthalmology (APAO) 2025, held in New Delhi, India from the 3rd to the 6th...At APAO 2025, Caregen aims to introduce the mechanism of action and clinical progress of CG-P5 and strengthen its technological leadership and position in the global ophthalmic market....Currently, CG-P5 is in the final stages of the US Food and Drug Administration (FDA) Phase 1 clinical trial, and a comparative clinical trial using Ilia as a control group is in progress. The clinical trial is scheduled to end around June, and an application for Breakthrough Therapy Designation (BTD) is being prepared."

Clinical • Trial completion date • Age-related Macular Degeneration • Wet Age-related Macular Degeneration

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Caregen Co. Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2024 ➔ Aug 2025 | Trial primary completion date: Oct 2024 ➔ May 2025

Enrollment open • Trial completion date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration

Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration (clinicaltrials.gov) - P1 | N=45 | Not yet recruiting | Sponsor: Caregen Co. Ltd.

Trial completion date • Trial initiation date • Trial primary completion date • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • Wet Age-related Macular Degeneration